ATC Group: A07DA Antipropulsives

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of A07DA in the ATC hierarchy

Level
Code
Title
1
Alimentary tract and metabolism
2
Antidiarrheals, intestinal antiinflammatory/antiinfective agents
3
Antipropulsives
4
A07DA
Antipropulsives

Group A07DA contents

Code
Title
Diphenoxylate
Loperamide
Difenoxin
Loperamide oxide
Morphine, combinations
Loperamide, combinations

Active ingredients in A07DA

Active Ingredient
Description

Diphenoxylate is a synthetic opioid derivative with selective effects on gastrointestinal smooth muscle. It is essentially devoid of “morphine type subjective effects” at therapeutic doses.

Eluxadoline is a locally acting, mixed mu opioid receptor (μOR) agonist and delta opioid receptor (δOR) antagonist. Eluxadoline is also an agonist at the kappa opioid receptor (κOR). Eluxadoline has demonstrated efficacy in normalizing GI transit and defecation in several models of stress induced or post GI inflammation-altered GI function in animals.

By binding to opiate receptors in the gut wall, loperamide hydrochloride reduces propulsive peristalsis, increases intestinal transit time and enhances resorption of water and electrolytes. Loperamide increases the tone of the anal sphincter, which helps reduce faecal incontinence and urgency.

Opium alkaloids (opioids and isoquinoline derivatives) induce constipation, euphoria, analgesia and sedation dependent on the dose and derivative. The constipating effect is caused by inhibition of the intestines' peristalsis.

Related product monographs

Title
Information Source
Document Type
 
Medicines & Healthcare Products Regulatory Agency (GB)
Summary of Product Characteristics (SPC)
Health Products Regulatory Authority (IE)
Summary of Product Characteristics (SPC)
Health Products and Food Branch (CA)
Structured Product Monograph (SPM)
Υπουργείο Υγείας (CY)
Summary of Product Characteristics (SPC)
Medicines & Healthcare Products Regulatory Agency (GB)
Summary of Product Characteristics (SPC)
Υπουργείο Υγείας (CY)
Summary of Product Characteristics (SPC)
Υπουργείο Υγείας (CY)
Summary of Product Characteristics (SPC)
FDA, National Drug Code (US)
Structured Product Labeling (SPL/PLR)